시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
허셉틴 시장 보고서(2025년)
Herceptin Global Market Report 2025
상품코드 : 1760550
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

허셉틴 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 6.1%의 연평균 성장률로 95억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 바이오시밀러의 확대, 표적 치료제의 채택 확대, 신흥 시장에서의 의료 접근성 향상, 진행 중인 암 분야 연구 개발, HER2 양성 암의 유병률 증가 등에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 항체약물접합체 개발, 바이오시밀러 제제의 발전, 신약개발에 AI의 통합, 맞춤형 의료 접근법, 약물전달 시스템 개선 등을 꼽을 수 있습니다.

유방암 발병률 증가가 허셉틴 시장 확대를 견인할 것으로 예상됩니다. 유방의 세포에서 발생하는 유방암은 일반적으로 유관이나 소엽에서 시작되며, 침윤성 유관암(IDC), 침윤성 소엽암(ILC), HER2 양성 유방암 등의 유형이 있습니다. 유방암 환자의 증가는 음주량 증가, 식생활의 변화, 운동 부족 등의 생활습관이 한 요인으로 작용하고 있으며, 이 모든 것이 위험도 증가에 기여하고 있습니다. 특히 HER2 양성 유방암 진단을 받고 치료를 원하는 사람들이 늘어남에 따라 허셉틴과 같은 효과적인 분자 표적 치료제에 대한 수요는 계속 증가하고 있습니다. 예를 들어, 미국 암학회는 2025년 1월 미국 내 유방암 신규 환자 수는 약 31만 9,750명, 사망자 수는 4만 2,680명에 달할 것으로 예측하고 있습니다. 따라서 유방암 발병률의 증가는 허셉틴 시장의 성장에 박차를 가하고 있습니다.

허셉틴 시장의 주요 기업들은 환자 접근성을 개선하고 HER2 양성 암의 치료 결과를 개선하기 위해 혁신적인 바이오시밀러 제품을 개발하고 있습니다. 바이오시밀러는 승인된 생물학적 제제의 고도로 유사한 버전으로, 동등한 안전성, 유효성 및 품질을 보장하기 위해 첨단 생명공학 기술을 활용하여 개발됩니다. 예를 들어, 미국 제약사 Accord BioPharma Inc.는 2024년 4월 HER2 과발현 유방암 및 위암 치료제로 허셉틴의 바이오시밀러인 HERCESSI(trastuzumab-strf)를 미국 식품의약국(FDA)으로부터 승인받았습니다. HERCESSI와 같은 바이오시밀러는 오리지널 생물학적 제제와 동등한 효능과 안전성을 유지하면서 환자에게 비용 효율적인 치료 옵션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, Herceptin inhibits tumor cell proliferation and marks them for destruction by the immune system.

The main products of Herceptin include biologics and biosimilars. Biologics are complex, large-molecule drugs derived from living organisms, used to treat various diseases, including cancer. The key payers include commercial, private, and public sectors, with applications in the treatment of breast and gastric cancers. Treatment is distributed through various channels, such as hospital pharmacies and specialty pharmacies.

The herceptin market research report is one of a series of new reports from The Business Research Company that provides herceptin market statistics, including herceptin industry global market size, regional shares, competitors with a herceptin market share, detailed herceptin market segments, market trends and opportunities, and any further data you may need to thrive in the herceptin industry. The herceptin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The herceptin market size has grown strongly in recent years. It will grow from$7.10 billion in 2024 to $7.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to regulatory approvals, the rising incidence of breast cancer, advancements in monoclonal antibody technology, positive clinical trial outcomes, and increasing healthcare expenditure.

The herceptin market size is expected to see strong growth in the next few years. It will grow to$9.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the expansion of biosimilars, increasing adoption of targeted therapies, improved healthcare access in emerging markets, ongoing research and development in oncology, and the rising prevalence of HER2-positive cancers. Key trends in the forecast period include the development of antibody-drug conjugates, advancements in biosimilar formulations, the integration of AI in drug discovery, personalized medicine approaches, and improvements in drug delivery systems.

The growing incidence of breast cancer is expected to drive the expansion of the Herceptin market. Breast cancer, which develops in the cells of the breast, typically starts in the milk ducts or lobules, and includes types such as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The rise in breast cancer cases is partly attributed to lifestyle factors such as higher alcohol consumption, poor diet, and a lack of physical activity, all of which contribute to a higher risk. As more individuals, particularly those diagnosed with HER2-positive breast cancer, are seeking treatment, the demand for effective targeted therapies such as Herceptin continues to grow. For instance, in January 2025, the American Cancer Society projected approximately 319,750 new cases of breast cancer in the U.S. with 42,680 expected deaths. Therefore, the increasing incidence of breast cancer is fueling the growth of the Herceptin market.

Leading companies in the Herceptin market are developing innovative biosimilar products to improve patient access and enhance therapeutic outcomes for HER2-positive cancers. Biosimilars are highly similar versions of approved biologic drugs, developed using advanced biotechnology to ensure comparable safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin, for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars such as HERCESSI provide patients with a cost-effective treatment option while maintaining comparable efficacy and safety to the original biologic drug.

In December 2022, Celltrion Inc., a South Korea-based biopharmaceutical company, merged with Celltrion Healthcare Co. to enhance its cost competitiveness and diversify its product pipeline. This merger is designed to streamline operations, boost research investments, and simplify the company's structure. Celltrion Healthcare Co., known for developing the Herceptin biosimilar Herzuma (trastuzumab-pkrb), which was approved by the FDA, is now positioned to further strengthen its global biopharma presence following this strategic merger.

Major players in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy's Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., and Prestige Biopharma Pte Ltd.

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in herceptin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the herceptin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The herceptin market consists of sales of trastuzumab, trastuzumab deruxtecan, and ado-trastuzumab emtansine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Herceptin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on herceptin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for herceptin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The herceptin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Herceptin Market Characteristics

3. Herceptin Market Trends And Strategies

4. Herceptin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Herceptin Growth Analysis And Strategic Analysis Framework

6. Herceptin Market Segmentation

7. Herceptin Market Regional And Country Analysis

8. Asia-Pacific Herceptin Market

9. China Herceptin Market

10. India Herceptin Market

11. Japan Herceptin Market

12. Australia Herceptin Market

13. Indonesia Herceptin Market

14. South Korea Herceptin Market

15. Western Europe Herceptin Market

16. UK Herceptin Market

17. Germany Herceptin Market

18. France Herceptin Market

19. Italy Herceptin Market

20. Spain Herceptin Market

21. Eastern Europe Herceptin Market

22. Russia Herceptin Market

23. North America Herceptin Market

24. USA Herceptin Market

25. Canada Herceptin Market

26. South America Herceptin Market

27. Brazil Herceptin Market

28. Middle East Herceptin Market

29. Africa Herceptin Market

30. Herceptin Market Competitive Landscape And Company Profiles

31. Herceptin Market Other Major And Innovative Companies

32. Global Herceptin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Herceptin Market

34. Recent Developments In The Herceptin Market

35. Herceptin Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기